

**WEDNESDAY, 12<sup>th</sup> SEPTEMBER 2018 COMMENCING 09:30 AM**  
**AT THE [COPTHORNE HOTEL CARDIFF](#), COTHORNE WAY,**  
**CULVERHOUSE CROSS, CARDIFF CF5 6DH**

**AGENDA**

**Enclosure**

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/0918
5. **Chairman's report (verbal update)**
6. **Appraisal 1: Limited Submission** 2/AWMSG/0918  
**Levonorgestrel (Kyleena<sup>®</sup>)** for contraception for up to 5 years Appendices
7. **Appraisal 2: Limited Submission** 3/AWMSG/0918  
**Lanreotide (Somatuline<sup>®</sup> Autogel<sup>®</sup>)** for the treatment of grade 1 and Appendices  
a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic  
neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or  
unknown origin where hindgut sites of origin have been excluded, in  
adult patients with unresectable locally advanced or metastatic  
disease
8. **Appraisal 3: Limited Submission** 4/AWMSG/0918  
**Octreotide (Sandostatin<sup>®</sup> LAR<sup>®</sup>)** for the treatment of patients with Appendices  
advanced neuroendocrine tumours of the midgut or of unknown  
primary origin where non-midgut sites of origin have been excluded
9. **National Prescribing Indicators 2017-2018 Analysis of Prescribing** 5/AWMSG/0918  
**Data to March 2018**
10. **Feedback from All Wales Prescribing Advisory Group meeting held** 6/AWMSG/0918  
**on 27<sup>th</sup> June 2018**

**Date of next meeting – Wednesday, 17<sup>th</sup> October 2018 in Cardiff**